AiRuiEn (rezvilutamide)

The patient had undergone laparoscopic radical prostatectomy 5 years prior and received intermittent postoperative endocrine therapy with leuprorelin acetate and bicalutamide...Following a change in the endocrine therapy regimen to rezvilutamide combined with degarelix, the patient's hematuria significantly improved. This case highlights the critical importance of rigorous postoperative surveillance and timely, standardized endocrine therapy in prostate cancer management. It also contributes to the limited literature on visceral metastases in castration-sensitive prostate cancer (HSPC) and underscores the need for further exploration of optimal treatment strategies for advanced metastatic disease.

P1, N=36, Completed, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Completed | N=18 --> 36

P3, N=670, Recruiting, AstraZeneca

P3, N=206, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | N=156 --> 206

P=N/A, N=43, The First Bethune Hospital of Jilin University; The First Bethune Hospital of Jilin University

P=N/A, N=30, The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university

P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting

P3, N=391, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=1256 --> 391 | Recruiting --> Terminated; Due to the adjustment of the sponsor's development plan, after discussion with leading PI, sponsor has decided to terminate this study.

P2, N=88, Active, not recruiting, Fudan University | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=192, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting

P2, N=300, Not yet recruiting, Fudan University

P=N/A, N=33, Not yet recruiting, Fujian Medical University Union Hospital